BIOGEN INC. (BIIB) FY2024 Annual Balance Sheet

Balance Sheet

As of 2024-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2024 Annual Balance SheetBalance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.Current liabilities$5.53 BCurrent assets$7.46 BLiabilities$11.33 BAssets$28.05 BNon-current liabilities$5.80 BNon-current assets$20.59 BEquity$16.72 BGross equity(calculated)$19.83 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSInventoryCash and cash equivalentsAccounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectivelyOther current assetsDue from anti-CD20 therapeutic programsIntangible assets, netGoodwillProperty, plant and equipment, netInvestments and other assetsOperating lease assetsDeferred tax assetAccrued expense and otherCurrent portion of notes payable and term loanTaxes payableAccounts payableNotes payable and term loanOther long-term liabilitiesLong-term operating lease liabilitiesDeferred tax liabilityRetained earningsAdditional paid-in capitalCommon stock, par value $0.0005 per shareCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury stock, at cost; 23.8 million and 23.8 million shares, respectivelyAccumulated other comprehensive income (loss)Accrued expense and otherAccrued expense and other$2.81 BCurrent liabilitiesCurrent liabilities$5.53 BCurrent portion of notes payable and term loanCurrent portion of notes payable and term loan$1.75 BInventoryInventory$2.46 BCurrent assetsCurrent assets$7.46 BLiabilitiesLiabilities$11.33 BTaxes payableTaxes payable$548.30 MCash and cash equivalentsCash and cash equivalents$2.38 BAccounts payableAccounts payable$424.20 MAccounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectivelyAccounts receivable, net$1.40 BAssetsAssets$28.05 BOther current assetsOther current assets$752.50 MNon-current liabilitiesNon-current liabilities$5.80 BNotes payable and term loanNotes payable and term loan$4.55 BDue from anti-CD20 therapeutic programsDue from anti-CD20 therapeutic programs$464.00 MOther long-term liabilitiesOther long-term liabilities$732.30 MLong-term operating lease liabilitiesLong-term operating lease liabilities$334.50 MNon-current assetsNon-current assets$20.59 BEquityEquity$16.72 BIntangible assets, netIntangible assets, net$9.69 BDeferred tax liabilityDeferred tax liability$190.50 MGross equity (calculated)Gross equity(calculated)$19.83 BGoodwillGoodwill$6.48 BRetained earningsRetained earnings$19.26 BProperty, plant and equipment, netProperty, plant and equipment, net$3.18 BInvestments and other assetsInvestments and other assets$560.50 MOperating lease assetsOperating lease assets$356.40 MAdditional paid-in capitalAdditional paid-in capital$569.40 MDeferred tax assetDeferred tax asset$324.20 MCommon stock, par value $0.0005 per shareCommon stock, par value $0.0005 per share$100.00 KTreasury stock, at cost; 23.8 million and 23.8 million shares, respectivelyTreasury stock−$2.98 BAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$136.20 M
Chart details

BIOGEN INC. (BIIB) FY2024 Annual Balance Sheet

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

Assets
28,049,300,000 US dollars
Current assets
7,456,800,000 US dollars
Non-current assets
20,592,500,000 US dollars
Liabilities
11,333,300,000 US dollars
Current liabilities
5,528,800,000 US dollars
Non-current liabilities
5,804,500,000 US dollars
Equity
16,716,000,000 US dollars
Inventory
2,460,500,000 US dollars
Cash and cash equivalents
2,375,000,000 US dollars
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively
1,404,800,000 US dollars
Other current assets
752,500,000 US dollars
Due from anti-CD20 therapeutic programs
464,000,000 US dollars
Intangible assets, net
9,691,200,000 US dollars
Goodwill
6,478,900,000 US dollars
Property, plant and equipment, net
3,181,300,000 US dollars
Investments and other assets
560,500,000 US dollars
Operating lease assets
356,400,000 US dollars
Deferred tax asset
324,200,000 US dollars
Accrued expense and other
2,807,700,000 US dollars
Current portion of notes payable and term loan
1,748,600,000 US dollars
Taxes payable
548,300,000 US dollars
Accounts payable
424,200,000 US dollars
Notes payable and term loan
4,547,200,000 US dollars
Other long-term liabilities
732,300,000 US dollars
Long-term operating lease liabilities
334,500,000 US dollars
Deferred tax liability
190,500,000 US dollars
Retained earnings
19,259,800,000 US dollars
Additional paid-in capital
569,400,000 US dollars
Common stock, par value $0.0005 per share
100,000 US dollars
Preferred stock, par value $0.001 per share
0 US dollars
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively
negative 2,977,100,000 US dollars
Accumulated other comprehensive income (loss)
negative 136,200,000 US dollars
Gross equity (calculated)
19,829,300,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
BIOGEN INC. (BIIB) FY2024 Annual Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!